Overview: FOXP3 TestIntroduction: The FOXP3 Test tests FOXP3 expression to diagnose immune dysregulation disorders like IPEX syndrome, causing autoimmune issues or infections, aiding in diagnosis. Affecting 1 in 1,000,000 people, IPEX syndrome poses diagnostic challenges due to its rarity. Following 2023 American Academy of Allergy, Asthma & Immunology (AAAAI) guidelines, it uses flow cytometry for high sensitivity, supporting hematology screening. This test is essential for diagnosis, treatment planning, and improving outcomes in immunology.
Other Names: FOXP3 Expression Test, IPEX Syndrome Assay.
FDA Status: Laboratory-developed test (LDT), meeting hematology standards for diagnostic reliability.
Historical Milestone: Immune marker testing began in the 1990s with research by Bennett, who linked FOXP3 to IPEX. Flow cytometry advancements in the 2000s by BD Biosciences improved detection, surpassing earlier immunohistochemistry methods.
Purpose: Measures FOXP3 expression to diagnose IPEX syndrome, guides immunosuppressive therapy, and evaluates patients with infections, aiming to manage immune dysfunction.
Test Parameters: FOXP3 expression
Pretest Condition: No special preparation required. Collect whole blood. Report history of immune issues.
Specimen: Whole Blood (EDTA, 2-5 mL); 4 mL whole blood in Na Heparin tube. Transport in a biohazard container.
Sample Stability at Room Temperature: 24 hours
Sample Stability at Refrigeration: 48 hours
Sample Stability at Frozen: Not recommended
Medical History: Document recurrent infections or autoimmune issues. Include current medications or family history of immune disorders.
Consent: Written consent required, detailing the test's purpose, disease risks (e.g., diabetes), and sample collection risks.
Procedural Considerations: Uses flow cytometry to measure FOXP3, requiring labs with flow cytometers. Results available in 1-2 days. Performed in labs with strict handling.
Factors Affecting Result Accuracy: Sample hemolysis or delay can affect results. Medications may alter expression, requiring correlation.
Clinical Significance: Abnormal expression confirms IPEX syndrome, guiding therapy. Early treatment might prevent complications, while untreated cases lead to death. Normal results may require genetic tests.
Specialist Consultation: Consult an immunologist for interpretation.
Additional Supporting Tests: Autoantibody panel, genetic testing, or biopsy to confirm diagnosis.
Test Limitations: Specific to FOXP3; correlation with symptoms needed. False negatives possible with atypical cases.
References: AAAAI Guidelines, 2023; Journal of Immunology, Bennett CL, 2022.
